Find information on thousands of medical conditions and prescription drugs.

DDAVP

Desmopressin (DDAVP®, Stimate®, Minrin®) is a synthetic drug that mimics the action of antidiuretic hormone, also known as arginine vasopressin. It may be taken nasally, intravenously, or through a recently developed pill. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Chemistry

Desmopressin (1-desamino-8-d-arginine vasopressin) is a modified form of the normal human hormone arginine vasopressin, an octapeptide (a chain of eight amino acids).

Compared to vasopressin, desmopressin's first amino acid has been deaminated, and the arginine at the eighth position is in the levo rather than the dextro form (see stereochemistry).

Method of action

Desmopressin binds to V2 receptors in renal collecting ducts, increasing water resorption. It also stimulates release of factor VIII from platelets due to stimulation of the V1a receptor.

Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension.

Uses

Desmopressin is used to reduce urine production in central diabetes insipidus patients and to promote the release of von Willebrand factor and factor VIII in patients with coagulation disorders such as type I von Willebrand disease, hemophilia A, and thrombocytopenia. Desmopressin is not effective in the treatment of hemophilia B.

It may also be prescribed to reduce frequent bedwetting episodes in children by decreasing noctural urine production.

Side effects

  • headaches
  • facial flushing
  • nausea

Read more at Wikipedia.org


[List your site here Free!]


Barr Laboratories
From Drug Store News, 8/22/05

Barr Laboratories received final FDA approval for its fexofenadine HC1 capsules in 60 mg strength, the generic version of Aventis Pharmaceuticals' Allegra, indicated for the relief of symptoms associated with seasonal allergic rhinitis and for treating uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children. Barr is entitled to 180 days of marketing exclusivity on the product.

In other news, Barr received final FDA approval for its generic version of DDAVP (desmopressin acetate) tablets in 0.1 mg and 0.2 mg dosages. Barr is the first to file an ANDA and is entitled to 180 days of marketing exclusivity. DDAVP tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. They also are indicated for the management of primary nocturnal enuresis. DDAVP had annual branded sales of $191 million per IMS Health data for the 12 months ended in April.

Barr also confirmed that Janssen Pharmaceutica Products and Synaptech filed suit against the company relating to the patents protecting Razadyne (galantamine hydrobromide), formerly called Reminyl, in 4 mg, 8 mg and 12 mg tablets. The drug is indicated for treating mild to moderate dementia of the Alzheimer's type. The suit officially initiates the patent challenge process under the Hatch-Waxman Act. Razadyne had annual branded sales of $247 million for the 12 months ended in April, according to IMS Health data.

COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group

Return to DDAVP
Home Contact Resources Exchange Links ebay